Johnson & Johnson $JNJ Shares Sold by Northeast Investment Management

Northeast Investment Management decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 174,167 shares of the company’s stock after selling 1,789 shares during the period. Northeast Investment Management’s holdings in Johnson & Johnson were worth $26,604,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. GFG Capital LLC acquired a new stake in Johnson & Johnson in the 2nd quarter valued at about $35,000. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.3%

Johnson & Johnson stock opened at $193.78 on Tuesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a 50 day moving average price of $180.89 and a 200 day moving average price of $165.18. The company has a market capitalization of $466.68 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion during the quarter. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on JNJ shares. Bank of America raised their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a report on Wednesday, October 15th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Citigroup raised their price target on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. Finally, Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a report on Wednesday, October 15th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $200.06.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.